Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.
View Top Employees from Rubius TherapeuticsWebsite | http://www.rubiustx.com |
Ticker | RUBY |
Revenue | $75 million |
Employees | 92 (92 on RocketReach) |
Founded | 2014 |
Address | 399 Binney St Suite 300, Cambridge, Massachusetts 02139, US |
Phone | (617) 679-9600 |
Technologies |
JavaScript,
HTML,
Twitter
+74 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Health Care, Therapeutics |
Web Rank | 2 Million |
Keywords | Rubius Therapeutics, Rubius Red Platform, Rubius, Rubius Therapeutics Pitch Deck, Rubius Thera |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Rubius Therapeutics employee's phone or email?
The Rubius Therapeutics annual revenue was $75 million in 2024.
Tamyra Toole is the Vice President Regulatory Affairs of Rubius Therapeutics.
92 people are employed at Rubius Therapeutics.
Rubius Therapeutics is based in Cambridge, Massachusetts.
The NAICS codes for Rubius Therapeutics are [32, 325, 3254, 32541].
The SIC codes for Rubius Therapeutics are [28, 283].